pemetrexed
Selected indexed studies
- Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. (Drug Saf, 2021) [PMID:34741752]
- Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. (J Clin Oncol, 2003) [PMID:12860938]
- Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. (Ann Oncol, 2021) [PMID:33894335]
_Worker-drafted node — pending editorial review._
Connections
pemetrexed is a side effect of
Sources
- Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. (2021) pubmed
- Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. (2003) pubmed
- Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. (2021) pubmed
- [Pemetrexed nephrotoxicity]. (2015) pubmed
- Safety of dose-reduced pemetrexed in patients with renal insufficiency. (2019) pubmed
- Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. (2022) pubmed
- Pemetrexed: a multitargeted antifolate. (2005) pubmed
- Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study. (2024) pubmed
- Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. (2021) pubmed
- Pemetrexed - First-Line Therapy for Non-Squamous Non-Small Cell Lung Cancer: A Review of Patent Literature. (2021) pubmed